PMID- 15904639
OWN - NLM
STAT- MEDLINE
DCOM- 20050705
LR  - 20161124
IS  - 0002-9149 (Print)
IS  - 0002-9149 (Linking)
VI  - 95
IP  - 11
DP  - 2005 Jun 1
TI  - Circulating levels of heart-type fatty acid-binding protein and its relation to 
      thallium-201 perfusion defects in patients with hypertrophic cardiomyopathy.
PG  - 1334-7
AB  - Myocyte loss and replacement fibrosis have been observed in patients with 
      hypertrophic cardiomyopathy (HC) with heart failure. This study was designed to 
      elucidate whether heart-type fatty acid-binding protein (H-FABP), a sensitive 
      biochemical marker for myocardial damage, indicates ongoing myocardial damage in 
      patients with HC. We studied 48 patients with HC and 17 control subjects. 
      Patients with HC were divided into 2 groups according to the New York Heart 
      Association (NYHA) functional class: NYHA I + II (n = 40) and NYHA III + IV (n = 
      8). Serum H-FABP and myoglobin levels were measured, and extent score was used to 
      assess the extent of thallium-201 perfusion defect. Serum H-FABP levels were 
      significantly higher in patients with HC than in control subjects (3.8 +/- 1.6 vs 
      2.6 +/- 0.7 ng/ml, p = 0.0032). Furthermore, serum H-FABP levels were 
      significantly higher in NYHA III + IV than in NYHA I + II (5.2 +/- 1.3 vs 3.5 +/- 
      1.5 ng/ml, p = 0.0043). Serum myoglobin levels showed no significant difference 
      among the 3 groups (control, 46.6 +/- 15.0 ng/ml; NYHA I + II, 55.5 +/- 26.4 
      ng/ml; NYHA III + IV, 65.1 +/- 33.6 ng/ml, p = 0.2115). Extent score correlated 
      positively with serum H-FABP levels (r = 0.420, p = 0.0026) and negatively with 
      fractional shortening (r = -0.542, p <0.0001). Increased H-FABP levels indicate 
      ongoing myocardial damage, which could result in clinical deterioration in 
      patients with HC.
FAU - Morioka, Norikatsu
AU  - Morioka N
AD  - The Second Department of Internal Medicine, Ehime University School of Medicine, 
      Ehime, Japan.
FAU - Shigematsu, Yuji
AU  - Shigematsu Y
FAU - Hamada, Mareomi
AU  - Hamada M
FAU - Higaki, Jitsuo
AU  - Higaki J
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Am J Cardiol
JT  - The American journal of cardiology
JID - 0207277
RN  - 0 (Biomarkers)
RN  - 0 (Carrier Proteins)
RN  - 0 (Fatty Acid-Binding Proteins)
RN  - 0 (Myoglobin)
RN  - 0 (Radiopharmaceuticals)
RN  - 0 (Thallium Radioisotopes)
SB  - IM
MH  - Aged
MH  - Biomarkers/*blood
MH  - Cardiomyopathy, Hypertrophic/blood/diagnostic imaging/*physiopathology
MH  - Carrier Proteins/*blood
MH  - Echocardiography
MH  - Fatty Acid-Binding Proteins
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myoglobin/blood
MH  - Radionuclide Imaging
MH  - Radiopharmaceuticals
MH  - Thallium Radioisotopes
EDAT- 2005/05/21 09:00
MHDA- 2005/07/06 09:00
CRDT- 2005/05/21 09:00
PHST- 2004/10/13 00:00 [received]
PHST- 2005/01/20 00:00 [revised]
PHST- 2005/01/18 00:00 [accepted]
PHST- 2005/05/21 09:00 [pubmed]
PHST- 2005/07/06 09:00 [medline]
PHST- 2005/05/21 09:00 [entrez]
AID - S0002-9149(05)00366-8 [pii]
AID - 10.1016/j.amjcard.2005.01.078 [doi]
PST - ppublish
SO  - Am J Cardiol. 2005 Jun 1;95(11):1334-7. doi: 10.1016/j.amjcard.2005.01.078.